Idelalisib Raises Eyebrows in LymphomaMedscapeTwo studies were presented providing results of the combination of each of these drugs with the classic R-CHOP [rituximab, cyclophosphamide, hydroxydaunorubicin, Oncovin (vincristine), prednisone]. One is a…
Antibodies in GI Tract Linked to Greater Risk for Bipolar IllnessPsychCentral.comAntibodies in GI Tract Linked to Greater Risk for Bipolar Illness A new study reveals that the gastrointestinal (GI) tract may be the starting point for the inflammation p…
New artificial protein mimics a part of the HIV outer coatThe AlmagestA team of scientists at Duke Medicine and Memorial Sloan-Kettering Cancer Center has created an artificial protein coupled with a sugar molecule that mimics a key site on the outer c…
Economic Times |
Roche, Prothena enter pact to co-develop & market antibodies for Parkinson’s …
pharmabiz.com Roche and clinical stage biotechnology company, Prothena Corporation have entered into a worldwide collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena’s monoclonal antibody for the treatment of … Roche, Prothena to develop new antibodies for Parkinson’s disease treatmentPharmaceutical Business Review Roche and Prothena to Devlop Antibodies for Parkinson’s DiseasePharmaceutical Processing Roche and Prothena Enter Into Worldwide Collaboration to Co-Develop and Co …4-traders (press release) Zacks.com –PMLiVE all 41 news articles » |
CLL Combos: And the Winner Is…MedscapeDr. Cheson: For years we have been arguing about use of fludarabine-cyclophosphamide (FC), fludarabine-rituximab (FR), fludarabine-cyclophasphamide-rituximab (FCR), or bendamustine-rituximab (BR). There have been…
OncLiveIdelalisib Improves Survival in High-Risk CLLOncLiveCombination treatment with the PI3K-delta inhibitor idelalisib and rituximab (Rituxan) was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/ref…
|
Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 …
SBWire (press release) Albany, NY — (SBWIRE) — 12/13/2013 — “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two … Monoclonal Antibodies Market in Colorectal Cancer to 2019 | Industry Shares …PR Web (press release) |
|
Gut bacteria lose their tails to evade antibodies
Futurity: Research News New research reveals the complex dynamic between gut bacteria and the immune system that keeps proteins from flagellin—bacterial tails—under control. In healthy individuals, the only thing that separates the lining of the human gut from the some 100 … |
|
Monoclonal Antibodies Market Research Report in Gastric and Esophageal …
SBWire (press release) Pharma report – “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the … |
|
Monoclonal Antibodies Market in Colorectal Cancer to 2019 | Industry Shares …
PR Web (press release) GBI Research, has released the pharma report – “Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth”. There are currently three monoclonal … Monoclonal Antibodies Market in Colorectal Cancer to 2019SBWire (press release) |